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Abstract 
 
Measurable residual disease (MRD, previously termed minimal residual disease) is an 
independent, post-diagnosis, prognostic indicator in acute myeloid leukemia (AML) that 
is important for risk stratification and treatment planning, in conjunction with other 
well-established clinical, cytogenetic, and molecular data assessed at diagnosis.  MRD 
can be evaluated using a variety of multi-parameter flow cytometry (MFC) and 
molecular protocols but, to date, these approaches have not been qualitatively or 
quantitatively standardized, making their use in clinical practice challenging. The 
objective of this work was to identify key clinical and scientific issues in the 
measurement and application of MRD in AML, to achieve consensus on these issues, and 
to provide guidelines for the current and future use of MRD in clinical practice.  The 
work was accomplished over two years, during four meetings by a specially designated 
MRD working party of the European LeukemiaNet (ELN). The group included 24 faculty 
with expertise in AML hematopathology, molecular diagnostics, clinical trials, and 
clinical medicine, from 19 institutions in Europe and the USA. The manuscript is 
dedicated to the memory of our esteemed colleague David Grimwade, a pioneer in the 
field of MRD in AML, and an active participant in the present work. 
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Introduction 
A myriad of factors present at diagnosis in acute myeloid leukemia (AML), including 
cytogenetics, molecular genetics, and age have been associated with prognosis, but still 
fall short in accurately predicting outcomes
1–3
 Increasing evidence now indicates that 
the ability to identify residual disease far below the morphology-based 5% blast 
threshold is an important tool for refining our approach to risk classiﬁcation. Minimal 
or, more appropriately, measurable residual disease (MRD) denotes the presence of 
leukemia cells down to levels of 1:10
4
 to 1:10
6
 white blood cells, compared to 1:20 in 
morphology-based assessments. There are several reasons to apply MRD detection in 
AML: 1) to provide an objective methodology to establish a deeper remission status, 2) 
to refine outcome prediction and inform post-remission treatment, 3) to identify 
impending relapse and enable early intervention, 4) to allow more robust post-
transplant surveillance, and 5) to use as a surrogate endpoint to accelerate drug testing 
and approval.  
Numerous studies have investigated the value of MRD in AML and have consistently 
shown that MRD negativity, as defined by specified cut-off values, is highly prognostic 
for outcome (see e.g. Table 1 for flowcytometric MRD). Reflecting the molecular 
diversity of AML, different MRD platforms are available for detecting MRD. Two 
methods are currently widely applied: multiparameter flow cytometry (MFC) and real-
time quantitative polymerase chain reaction (RQ-PCR), while newer technologies, 
including digital PCR and Next Generation Sequencing (NGS), are emerging. Each 
methodology differs in the proportion of patients to whom it can be applied and in its 
sensitivity to detect MRD. It is expected that integration of baseline factors and 
assessment of MRD will improve risk assessment.
4
  MRD assessments are performed in 
an increasing number of laboratories worldwide and used in various clinical settings. 
However, no guidelines or recommendations are available on how and when to apply 
MRD assessments, and how to translate the results to clinical practice. An international 
group of experts addressed these issues on behalf of the European LeukemiaNet (ELN) 
and reports here on its conclusions. 
 
Methods 
An international panel of 24 experts, including 19 from European countries and 5 from 
the United States, met four times during 2016 and 2017, with numerous email 
5 
 
exchanges during this time. The panel included members with recognized technical, 
clinical, and translational knowledge of MRD in AML, including specific expertise on MFC 
MRD, molecular MRD, NGS, and clinical issues. For the clinical section, only MRD 
publications including at least 50 patients were reviewed (Table 1).  Unpublished 
technical details from individual laboratory directors were also discussed and used. In 
several areas, there was inadequate data to draw firm conclusions. 
The final ELN MRD recommendations are subdivided in three parts: MFC, molecular, and 
clinical. The paper presents a summary of consensus and non-consensus issues, with 
extended views present in Supplementary text under headings corresponding to those 
in the main document. 
 
Flowcytometric (MFC) MRD  
 
Approaches for MFC MRD assessment (LAIP versus different-from-normal)    
For the detection of MRD, a comprehensive panel characterized by early marker(s) like 
CD34 and CD117, myeloid-lineage associated markers, and differentiation antigens like 
CD2, CD7, CD19 or CD56, must track aberrant AML blast cells. 
Two separate approaches have been used for assessing MFC MRD: 1) the LAIP approach, 
which defines Leukemia Associated Immunophenotypes at diagnosis and tracks these in 
subsequent samples; 2) the Different-from-Normal (DfN) approach that is based on the 
identification of aberrant differentiation/maturation profiles at follow up. The DfN 
approach can be applied if information from diagnosis is not available, and also to detect 
new aberrancies, together with disappearance of diagnosis aberrancies, referred to in 
earlier literature as “immunophenotype shifts”
5–7
  These may emerge from leukemia 
evolution or clonal selection. 
8,9,10
 In essence, LAIPs are DfN abnormalities in the vast 
majority of cases, and the difference between these two approaches is likely to 
disappear if an adapted, sufficiently large panel of antibodies (preferably ≥ 8 colors) is 
utilized. 
We recommend that the advantages of both approaches be combined to best define MFC 
MRD burden, allowing detection of new aberrancies emerging at follow-up and monitor 
patients when there is an absence of diagnostic information.  
The ELN MRD working party suggests the term ‘LAIP-based DfN approach’ for this 
combined strategy. To be more specific, aberrancies may be referred to as LAIPs or DfN-
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LAIP, whichever is the more appropriate term. LAIPs and DfN-LAIPs can be further 
categorized as 1) diagnostic, 2) follow-up (based on diagnosis information), 3) follow-up 
(no diagnostic information) 4) changed (i.e. new aberrancy compared to diagnosis LAIPs 
or previous follow-up LAIPs). 
Suggestion for further improvements: 
We recommend to use the integrated LAIP-based DfN approach to separately validate 
the, largely unknown, prognostic impact of emerging aberrancies. 
 
Markers for MRD assessment 
Marker Panel content. Many different panels of markers have been used to assess MRD 
(for the panels currently used by the ELN Working Group members, see Suppl. Table 1).  
Based on the collective experiences of the working group, a two-step consensus 
recommendation is proposed, that includes gating on CD45, sideward scatter (SSC), 
forward scatter (FSC), a primitive marker (CD34, CD117), and abnormal expression of 
marker(s) or abnormal combination(s) of marker expression. In addition, a monocytic 
combination, including CD64, CD11b and CD4 (see legends of Suppl. Table 1), is 
proposed to assess MRD in monocytic or myelomonocytic AML.
11,12
 
Other interesting markers are in Suppl. Table 1, and include CD133, CD38 and CD123 
that allow to define more primitive progenitor and/or leukemia stem cell 
populations.
13,14
 
Number and nature of fluorochromes. We recommend using a minimum of eight colors. 
Although not formally proven, this may allow more specific assessment of aberrancies 
than is feasible with fewer colors. 
Rather than recommending suitable clones and fluorochromes, the panelists suggest 
taking advantage of extensive validation studies as done, for example, by the Euroflow 
consortium
15
 and the French GEIL group (consensus document in revision). Specific 
attention should be given to Staining Index of fluorochromes (see Suppl. text). 
Using the same tubes (with the same antibody-fluorochrome combinations) at diagnosis 
and at follow-up is considered a prerequisite for the LAIP-based DfN approach of 
tracking of both LAIPs established at diagnosis and emerging aberrancies.   
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Suggestions for further improvements: 
1. To minimize the number of different panels used, we strongly recommend the design 
and validation of a single common panel-assay, preferably as an ELN initiative, for all 
MRD studies.
16
 
2. We recommend exploration of the value of a separate (single tube) LSC panel (see 
Suppl. Figure 1)  in which the total LSC load can be assessed at any time from diagnosis 
to relapse.
17
 Validation of such a panel has been initiated amongst different ELN and 
non-ELN members.  
Technical requirements  
Bone marrow sampling. Sampling for MFC MRD usually is done in such anti-coagulants 
as EDTA or heparin, with no significant difference between these. A recurrent concern is 
that MFC MRD in peripheral blood (PB) is characterized by a lower frequency than in 
BM (up to approximately 1 log.
18,19
). The use of PB at present cannot be recommended.
20
 
To maximize assay sensitivity, it is mandatory to avoid hemodilution of BM samples. We 
therefore strongly recommend to submit the first BM pull for MRD analysis, at least for 
follow up BM samples intended for MFC MRD, preferably using the same volume across 
time points and patients. It is recommended to estimate the possible contamination with 
PB, the presence of more than 90% mature neutrophils in a BM sample indicating 
significant hemodilution.
20–24
 Sampling time points and volumes for MFC (and 
molecular) assays are outlined in Suppl. Table 2.   
 
Bone marrow transport. In the multicenter setting, we recommend transport at 
controlled room temperature. Up to three days storage is allowed, without the need for a 
viability marker, provided BM is stored undiluted. 
 
Flow cytometers. Basic principles of flow cytometric settings have been described for many 
purposes including MRD.
25–27
 Harmonization of instrument settings is of high value for inter-
laboratory comparison of results. One robust, simple way to assess this harmonization has 
been described by the Harmonemia study.
27
 The Euroflow consortium also provided 
standard operating procedures for their panels.
25
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Preparation of samples. There are two major approaches for preparing BM samples for FCM: 
1) stain/lyse/wash (or no wash), has the advantage of reducing cell losses; 2) bulk lysis 
followed by washing, staining (and washing) has the advantage of having all tubes prepared 
in a similar way for the different staining steps. Both approaches are in use for AML MRD 
assays. Incubation typically should be performed in the dark to preserve the quality of 
fluorochromes. The greater skill, with no consensus at the moment, resides in the analysis 
step, typically using a series of linked gatings aiming at best identifying the MRD population. 
Comparison with the diagnosis pattern is the safest, seeking for residual cells of the same 
population as that seen at diagnosis. However, in some instances, a clearly focused 
population, differing from the initial one, can be seen. It may represent a shift of the initial 
clone/population or the emergence of a chemotherapy-resistant sub-population. Whether this 
will lead to relapse is impossible to determine, but it is recommended that in such instances 
closer surveillance of the patient is suggested. 
 
How to calculate MRD burden and minimal requirements 
Several strategies have been used to quantify the MRD burden. To harmonize reporting we 
recommend the following.   
1) Use LAIPs that clearly occupy an empty space, ie aberrancies not found at the same MFC 
location in control BM, at diagnosis and follow up. In cases where only part of a population is 
occupying an empty space, inclusion of additional cells outside the empty space is allowed 
provided they define one single clustered population together with the cells from the empty 
space.  
2) Use the best (most specific and/or highest frequency) LAIP for assessing MRD frequency; 
in case of multiple, non-overlapping LAIPs, frequencies of individual LAIPs should be added 
up. 
3) Relate LAIP events to the leukocyte population of CD45
+
 cells (excluding CD45
-
 
erythroblasts). 
4) Use the diagnosis LAIPs if diagnosis sample and diagnosis LAIPs are available to optimally 
inform MRD gating for these LAIPs.   
5) Use the DfN approach to identify any new LAIPs. Such new LAIPs can be used for 
quantitation. 
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It is also recommended to acquire between 500,000-1 million events (excluding all CD45-
negative cells and debris) unless the cluster of MRD becomes obvious during acquisition and 
is recognized by a trained operator.  
Suggestion for further improvements: 
In order to minimize subjectivity in data-interpretation/-analysis, it is recommended to 
evaluate the possibilities for improved discrimination of LAIPs achieved by 
multiparameter displays, such as principal component analysis (PCA) in commercially 
available programs, e.g. in the APS system of the Kaluza
®
 or Infinicyte
®
 programs. 
Several initiatives are ongoing to develop and/or apply more sophisticated analysis 
programs. 
 
Thresholds and time points for MRD assessment during treatment 
The present concept is to use MRD for risk analysis at an early time point prior to 
consolidation therapy. With the large number of aberrancies that can be defined (up to 
one hundred
28
 and their inherent differences in specificity, cut-off levels that capture 
MRD positivity applicable to all LAIPs, have to be relatively high, ie 0.035% to 0.2% 
(Table 1, and Table 2 in Ossenkoppele and Schuurhuis
29
). A cut-off of 0.1% was included 
and found relevant in most published studies to date and, thus, we recommend using 
0.1% as the threshold to distinguish MRD-positive from MRD-“negative” patients. 
However, it should be noted that MRD tests with MRD quantified below <0.1% may still 
be consistent with residual leukemia, and several studies have shown prognostic 
significance of MRD levels below 0.1%.
12,29–32
 Thus cut-off levels below 0.1% e.g. <0.01% 
may define patients with particularly good outcome. 
Suggestion for further improvements:  
To perform retrospective analyses for patients with MRD burden <0.1% but >0% versus 
≥0.1%.  
 
Thresholds and time points for MRD assessment during follow up/definition of 
relapse  
In general, the definition of MRD positivity after consolidation therapy is similar to the 
post-induction definition.
33
. Not much is known about the optimal time intervals for 
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clinically relevant sequential measurements of MRD.
34
 More information on such time 
intervals is reported in molecular MRD studies (see below). 
Suggestion for further improvements: 
With the emergence of potential novel remission treatment options in AML, there is 
urgent clinical need to establish the optimal intervals needed to define 
progression/impending relapse. Unpublished data from several institutions exist on 
sequential MRD measurements, and may be informative.  
 
Design of MRD studies: multicenter versus single center approaches 
To facilitate and optimize data from MRD studies, we recommend that for multicenter 
studies samples may be processed by different centers applying the same MRD panels, 
according to the recommendations offered in the present paper. With insufficient 
experience in MRD analysis, the final interpretation should be performed at a central 
institute or in a group workshop. Alternatively, samples may be sent under carefully 
controlled conditions (see Technical requirements) to a central institute for work-up 
and analysis. The advantages of such centralized approach need to be weighed against 
the disadvantages, for example delays in processing and/or in establishing a final report 
for clinical decision making. For single center studies in institutions with relevant 
experience, we recommend following the procedures described in this paper. Single 
center studies without relevant experience are strongly discouraged. The present local 
policies of the ELN Working Group members are outlined in Suppl. Table 3. 
Suggestion for further improvements: 
With the increasing number of centers embarking on MRD studies, it is strongly 
recommended to establish working relationships with experienced centers. Meanwhile, 
we hope, and will support, that community practices and commercial laboratories seek 
opportunities to design common panels and procedures. 
How to report MRD 
In general, the minimum number of cells needed for accurate reporting of MRD is 
500,000-1 million, excluding all CD45-negative cells and debris, although lower cell 
numbers may still suffice if the level of MRD is relatively high, and notably to merely 
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assess a positive/negative status based on the 0.1% (10
-3
) threshold. The high numbers 
enable to assess possible MRD below the level of 0.1% (see below: point 4). 
Reports on MRD status should be constructed to allow the clinicians to draw clear 
conclusions about how to interpret the report. Elements in an MRD report should 
contain the following parameters (see also Figure 1A &B):  
1. A) Absolute numbers of LAIP and WBC, and LAIP cells as percentage of WBC; B) For 
diagnostic  LAIPs, the percentage coverage of blast cells at diagnosis; C) Clinicians and 
laboratory staff should collaborate to decide if the final report will contain a statement 
“MRD-positive” or “MRD-negative” (ie MRD ≥0.1% or <0.1%). In cases with complete 
absence of aberrancies, the term “no MFC MRD identified” can be added to report of 
“MRD negative”.  
2. Detection sensitivity threshold for the aberrancy used with details: all aberrancies 
have the 0.1% threshold level, but additional information about the particular nature 
(sensitivity/specificity) of an aberrancy may be important, for example nature of 
myeloid, primitive, aberrant and exclusion marker, especially in cases of newly defined 
LAIPs not present at diagnosis. 
3. Comments on quality of the sample, for example viability, insufficient regeneration, 
PB contamination (Figure 1B). For suboptimal samples with detectable MRD, numbers 
of LAIP
+
 cells need to be communicated. 
4. It is up to the clinician (or clinical study group) how to deal with information for 
MRD<0.1%: the report could contain “MRD detectable but <0.1%, may be consistent with 
residual leukemia” but also the statement “this level has not been clinically validated” 
when applicable for the laboratory involved. Alternatively, MRD <0.1% may be reported 
as “MFC MRD detectable and quantifiable, but with uncertain significance”. Leaving out 
such information may have medico-legal consequences.  
An example of a report form is shown in Figure 1B.    
Suggestion for further improvements: 
As outlined earlier, very low levels of MRD (<0.01%) differentiate patients with a 
particularly good prognosis in some studies. Meta-analysis of prognostic models from 
other study groups, as well as independent validation of these very low threshold levels, 
may be of clinical importance.  
12 
 
Future directions  
Retrospective analyses of databases to establish the value of the DfN versus LAIP 
approach in terms of prognostic impact, further exploration of the value of LSC detection 
in prognosis and the urgent need for testing automated data analysis programs, are of 
great importance in future studies of MRD in AML. 
Optimizing the use of PB for MRD analysis, if feasible, would reduce the need for painful, 
time-consuming, and expensive BM testing.
18,19
 For the moment, PB MRD may offer a 
“first indication”, but BM MRD should always be assessed to define the MRD status of the 
patient (“positive” or “negative”).  
As a final area of investigation, in contrast to molecular MRD, nothing is known about 
the possible relationship between pre-leukemic populations and immunophenotypic 
aberrancies. Investigation of this potential relationship may become important in the 
future. 
 
Molecular MRD  
 
Approaches for molecular MRD assessment 
There are two general approaches to molecular MRD assessment: real-time PCR-based 
approaches, and sequencing approaches wherein sequences from individual DNA/cDNA 
molecules are generated.  
The PCR approach includes classical quantitative real time PCR (qPCR) using fluorescent 
probes, digital PCR, and molecular chimerism analysis.
35
 This approach is usually of high 
sensitivity and therefore currently considered the gold standard. However, its 
applicability is limited to the approximately 40% of AML patients that harbor one or 
more suitable abnormalities.  
Next generation sequencing for MRD assessment can, theoretically, be applied to all 
leukemia specific genetic aberrations. With improved experimental and bioinformatics 
approaches, we expect this approach to become applicable for another 40-50% of AML 
patients.  
In general, we suggest that a MRD platform should be able to detect leukemic cells to a 
level of 0.1% (1 in 1000 mutated cells). We recommend the use of real time qPCR 
platforms for MRD assessment due to their established high sensitivity. In the future, it 
13 
 
is likely that NGS and digital PCR platforms will be used after careful validation. 
Genescan-based fragment analysis (e.g for FLT3 aberrations) has a low priority as a 
MRD platform due to limited sensitivity.  
  
Markers for molecular MRD assessment 
The persistent presence of NPM1 mutations and the fusion genes RUNX1-RUNX1T1, 
CBFB-MYH11 and PML-RARA following therapy is a strong predictor of relapse. Thus, 
patients with these abnormalities should have molecular assessment of residual disease 
using qPCR (sensitivity 10
-4
 to 10
-6
) at informative clinical time points (see below).  
Pre-leukemic founder clones (and associated mutations; typical examples are those 
observed for DNMT3A, ASXL1 and TET2 genes) may persist at significant levels, even 
upon achievement of complete morphological remission,
36–38
 but the detection of these 
may not reliably represent the presence of AML MRD and may not be of prognostic 
significance. Mutations in these genes also occur in healthy individuals with increasing 
frequency as they age.
39,40,41
 This is referred to as age-related clonal hematopoiesis 
(ARCH) or clonal hematopoiesis of indeterminate potential (CHIP).
42
 In AML, such 
mutations often occur very early in the process of malignant transformation. 
31,36,38,43,44
 
For many other acquired mutations (that may occur later during disease development), 
it is unknown whether they represent reliable AML MRD markers.  
Several genes mutated in germline are associated with a risk of AML development like 
RUNX1, GATA2, CEBPA, DDX41, ANKRD26.
44
 Naturally, they will not correlate with 
disease burden, and while remaining at a variant allele frequency of 50%, will not be 
useful for MRD assessment. If nevertheless potential somatic mutations in these genes 
are used as MRD markers, we recommend excluding germline origin by DNA sequencing 
from germline tissue (skin biopsy, hair follicle or buccal swab). Germline origin or CHIP 
should be suspected and excluded if the mutation level is unchanged compared to 
diagnosis, despite decreased blast count. 
WT1 expression
45,46
 (Table 2) should not be used as MRD marker, due to low sensitivity 
and specificity,  unless no other MRD markers, including flow cytometric ones, are 
available in the patient. If nevertheless WT1 is used, it should follow the validated WT1 
MRD assay
45
 developed by ELN researchers,  and preferably in PB. 
In patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) 
the analysis of donor/recipient chimerism in PB and/or BM has been suggested as MRD 
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marker. The conventional detection method using fragment analysis of short tandem 
repeats has limited sensitivity and therefore is not recommended for MRD.
47
 Modern 
techniques may allow higher sensitivity.
35
 In addition, variant allele-specific qPCR 
detecting small DNA insertions or deletions may be used as a sensitive method (10
-3
) to 
detect autologous cells.
48,49
 
Due to frequent losses or gains of certain mutations at relapse, we also recommend 
against the use of mutations in FLT3-ITD, FLT3-TKD, NRAS, KRAS, IDH1, IDH2, MLL-PTD, 
and expression levels of EVI1 as single markers of MRD. However, several of these not-
recommended markers may have more prognostic significance when used in 
combination with a second MRD marker.  
Suggestions for further improvements: 
1. The combination of several markers for MRD assessment can overcome limitations of 
MRD assessment that are due to sub-clonal heterogeneity of AML and to CHIP. Such 
combination analysis will become increasingly feasible with advances in NGS MRD. For 
example, a patient may present with mutations in TP53, ASXL1 and PTPN11. In 
complete remission, the ASXL1 mutation may persist at a high VAF due to clonal 
hematopoiesis and cannot further be used for MRD assessment. The PTPN11 mutated 
clone may be successfully eradicated by chemotherapy. However, the TP53 mutated 
clone may persist and be part of the relapse-inducing clone. Thus, analysis of several 
MRD markers in one patient may increase the likelihood to identify molecular relapse. 
2. In alloHSCT patients germline variants in genes associated with hematopoietic 
malignancy and mutations associated with CHIP should be evaluated as markers of 
recipient hematopoiesis to monitor MRD in the future.  
Technical requirements for molecular MRD assessment 
For reasons of sensitivity for qPCR, we recommend the use of cDNA over DNA for genes 
that are well expressed in AML cells (for technical details, see Suppl. Text “Technical 
requirements”). For new MRD markers, the expression level in AML cells should be 
evaluated. Detailed recommendations for MRD assays detecting RUNX1-RUNX1T1, CBFB-
MYH11 and PML-RARA have been published by the Europe Against Cancer initiative, 
including appropriate housekeeping genes .
50,51
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Each MRD analysis by PCR should be run in triplicate. Amplification in at least two of 
three replicates with Ct values ≤ 40 (at a cycling threshold of 0.1) is required to define a 
result as PCR positive according to EAC criteria.
50
 As controls, we recommend including 
a wild type sample (normal control), at least two positive controls that cover the desired 
sensitivity range, and a non-target control (water control). If the positive controls are 
generated from plasmids, the stability of the plasmids should be monitored regularly.  
After conversion of MRD from negative to positive, we recommend two specific 
measures to control for assay variability in the repeat samples: first, the initial sample in 
which molecular relapse was suspected should be included during the measurement of 
the repeat sample. Second, if the MRD assay is a real-time qPCR assay, standards should 
be included that cover the CT range of the patient samples to ensure linearity of the 
assay at the measured MRD level. If a negative MRD measurement is obtained, it is 
essential to know the sensitivity level at which it was determined. The following formula 
has been suggested to calculate the sensitivity of an individual real-time qPCR 
measurement, which can be used for absolute quantification using an external plasmid 
calibrator to estimate numbers of target molecules, as well as for relative 
quantification
52,53
: 
X = [(CT
target
-CT
ABL
)
MRD
 - (CT
target
-CT
ABL
)
diagnosis
]/slope 
Assay sensitivity = 10
X
 
(slope = slope of the standard curve, for an assay with 100% efficiency =-3.32) 
We recommend reporting the individual assay sensitivity in patients with complete 
molecular remission.  
 
Tissue sampling and time points for MRD assessment during treatment 
The details of sampling time points and corresponding tissue source are outlined in 
Suppl. Table 2, and Suppl. text (under “Tissue sampling for MRD assessment”) During 
the treatment phase we recommend molecular MRD assessment at minimum at 
diagnosis, after 2 cycles of standard induction/consolidation chemotherapy and after 
the end of treatment in PB AND BM, as MRD in PB may provide better prognostic 
stratification. For patients undergoing alloHSCT, MRD should be assessed in PB and BM 
after the last conventional chemotherapy, but not earlier than 4 weeks before 
conditioning treatment. The recommended thresholds for MRD positivity are discussed 
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in the clinical section. The risk of relapse and overall survival probabilities for different 
MRD thresholds and constellations in prior studies are shown in Table 2.   
Tissue sampling and time points for MRD assessment during follow up and 
definition of complete molecular remission, molecular persistence at low copy 
number, molecular progression and molecular relapse 
In general, for patients with PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11, mutated NPM1 
and other molecular markers, we recommend molecular MRD assessment every 3 
months for 24 months after the end of treatment in BM and in PB. Monitoring beyond 2 
years of follow up should be based on the relapse risk of the patient and decided 
individually. The prognostic impact of different MRD levels in follow-up is summarized 
in Table 2.  
In this section and in Suppl. Table 4 we specify outcome criteria of molecular MRD based 
on the depth of remission at the end of the treatment phase. Patients with complete 
morphologic remission after treatment may be in complete molecular remission (CR
MRD
) 
or may have molecular persistence at low copy numbers. Patients in CR
MRD-
 may develop 
molecular relapse and patients with molecular persistence may develop molecular 
progression. It is not known yet whether molecular relapse and molecular progression 
have similar clinical characteristics or outcomes. Therefore, we currently recommend 
distinguishing between molecular progression and molecular relapse. In the following 
we shortly define these terms, and in Supplementary text (“Time points for MRD 
assessment…”) and Suppl. Table 4, the recommended frequencies of monitoring and 
preferable tissue source are outlined.   
Complete molecular remission (CR
MRD-
). To determine complete molecular remission 
(CR
MRD-
) a patient must be in complete morphologic remission (CR). We define CR
MRD-
 
as two successive MRD negative samples obtained within an interval of ≥ 4 weeks at a 
sensitivity level of at least 1 in 1000. Negative MRD in the presence of blasts suggests 
molecular loss of the particular marker. 
 
Molecular persistence at low copy numbers. Molecular MRD may persist at low copy 
numbers, which is associated with a low risk of relapse. To label these patients we 
suggest the definition of molecular persistence at low copy numbers, which we 
define as MRD with low copy numbers in patients with morphologic CR (<100-200 
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copies/10
4
 ABL copies corresponding to <1-2% of target to reference gene or allele 
burden)
54,55
 and a copy number or relative increase < 1 log between any two positive 
samples collected after the end of treatment.  
 
Molecular progression. We define molecular progression in patients with molecular 
persistence at low copy number as an increase of MRD copy numbers ≥ 1 log
10
 between 
any two positive samples.  
  
Molecular relapse. Patients in complete morphologic remission who achieve molecular 
remission may convert to positive MRD. We define molecular relapse as an increase of 
the MRD level of ≥ 1 log
10
 between two positive samples in a patient who previously 
tested negative in technically adequate samples.  
How to report molecular MRD results 
The recommended parameters that should be included in a report of molecular MRD 
assessments are listed in Suppl. Table 5. We recommend to report absolute copy 
numbers for RT-PCR results, in addition to the fold increase, to enable the clinician to 
make his/her own judgments. 
 
Future directions 
As discussed above, the predictive power of several mutations is low or needs to be 
clarified. For frequently occurring point mutations, this is challenging because with 
current routine NGS approaches, the sensitivity of detecting these is ~1%. A higher 
sensitivity of detecting point mutations can be obtained with digital droplet PCR (details 
in Suppl. Text).
56
 A disadvantage of ddPCR is that for each mutation a specific assay 
needs to be developed. Because this is time consuming and costly, this assay is especially 
suitable for sensitive detection of recurrent mutations like for instance in IDH1 and 
IDH2. Recent developments including error-corrected NGS also allow for highly sensitive 
point mutation detection (details in Suppl. Text).
57–59
 A significant advantage of this NGS 
approach is that multiple mutations can be analyzed in one single patient sample. 
However, this approach does require more bioinformatic processing of data. Ultimately, 
this approach should provide greater sensitivity and, if adopted on BM and PB, may be 
able to identify low level mutations in terminally mature myeloid and lymphoid cells in 
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PB; mutations of this nature are typically associated with clonal hematopoiesis and not 
leukemia.  
  
Clinical paragraph on MRD 
 
MRD in clinical AML studies  
During the last 20 years, numerous single institution studies in adult and pediatric 
patients have established that, regardless of the detection technique (MFC, RT-PCR, or 
NGS) and irrespective of hematopoietic cell transplantation (HCT), presence of MRD is 
associated with increased relapse risk and shorter survival in AML.
4,16,60
 Using a cut-off 
at a specified MRD detection threshold, the two resulting patient groups are referred to 
as “MRD positive” and “MRD negative”, although the latter is an oversimpliﬁcation since 
improved outcomes do not necessarily require undetectable levels of MRD, while, 
inversely, a minority of MRD-negative patients will relapse as well.
4,16
 
Two large, prospective, multicenter studies (details in Suppl. text) have identified flow 
cytometry-based MRD as an independent prognostic indicator in adults with AML.
28,30
 In 
both studies MRD positive patients had poorer outcome in multivariate analyses. 
28,30
 In 
contrast to MFC, molecular assays enable MRD tracking in only a subset of patients.
4
 
Currently, validated molecular MRD targets in AML include the PML-RARA translocation 
in acute promyelocytic leukemia (APL), core-binding factor (CBF) translocations, and 
mutations in NPM1.
4,16,61
 As an example NPM1-based MRD presented as the only 
independent prognostic factor for death in multivariate analysis.
61
 Details are in Suppl. 
text. 
Measurements of MRD using NGS techniques are under development, but are not ready 
for routine application outside of clinical trials.
57–59
 Therefore, the current gold-standard 
measurements of MRD utilize complementary molecular and MFC-based techniques. 
Based on that, the following guidelines were constructed to facilitate the routine 
evaluation of MRD for AML patients in clinical practice, as well as for those participating 
in investigational trials.  
 
General principles for clinical practice 
In AML, morphology-based assessments of CR can be meaningfully refined with 
additional information about MRD.
62,63
 This is reflected in the 2017 ELN AML 
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recommendations, which now include MRD as a new response criterion (CR 
with/without MRD).
64
 MRD monitoring should be considered part of the standard of 
care for AML patients. For molecular MRD this is limited to APL, CBF AML, and NPM1-
mutated AML. For other AML patients, MRD should be assessed using MFC.
4
 This 
recommendation may change over time with emerging data for other molecular sub-
groups.  Failure to achieve an MRD-negative CR, or rising MRD levels during or after 
therapy are associated with disease relapse and inferior outcomes and should prompt 
consideration of changes in therapy, preferably in the setting of a controlled clinical 
trial.
61,65
  Although a rather rare event, it will have to be decided how to deal with 
patients who are not in morphological CR, but are in CR based on MRD assessment. 
There are two concerns as to the clinical application of MRD: first, the use of cut-off 
levels in chemotherapy-based therapies generally reveals that different cut-off levels 
have different meaning in different  risk groups in terms of patient outcome, and 
secondly, knowledge  on the significance of MRD for patients treated with non-intensive 
therapies, for example DNA methyltransferase inhibitors (“hypomethylating agents”) is 
currently limited.
66
 We nevertheless suggest that such patients should be monitored for 
MRD with the caveat that there are few data to guide interpretation of MRD results.  
 
Acute promyelocytic leukemia 
In APL, the most important MRD endpoint is achievement of PCR-negativity for PML-
RARA at the end of consolidation treatment, either with ATRA + chemotherapy-based or 
ATRA + arsenic trioxide-based therapies. PCR negativity at the end of consolidation is 
associated with a low risk of relapse and a high chance of long-term survival (see Table 
2).
67,68
 Detectable levels of PML-RARA by PCR during active treatment of APL should not 
change the treatment plan for an individual patient and it is controversial whether serial 
PCR measurements of PML-RARA during treatment are of value outside of clinical 
trials.
65,69
 
At the completion of therapy,  a change in status of PML-RARa by PCR from undetectable 
to detectable, as measured in either BM or PB and confirmed by a repeat sample, heralds 
imminent disease relapse in APL.
64,67
  
For patients with low- and intermediate risk disease (by Sanz Score
70
), who are treated 
with an ATRA and anthracycline-based regimen, monitoring in BM at completion of 
induction therapy and in BM or PB every 3 month for the first two years after remission 
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is recommended. For patients with low/intermediate risk Sanz score who are treated 
with ATO and ATRA, MRD analysis should be continued until the patient is in CR
MRD-
 in 
BM and then should be terminated.
67
 For patients with high-risk APL, BM or PB 
monitoring is recommended every 3 months after completion of therapy for at least two 
years. Early identification of molecular relapse could fasten clinical action, e.g. reducing 
bleeding complications but impact of early detection on clinical outcome has not been 
shown.
65
 Finally, the presence of a FLT3 mutation should neither change clinical 
management, nor demand serial monitoring.
 
 
Core Binding Factor (CBF) AML 
CBFB-MYH11 (Inv(16)). 
Despite the prognostic value of MRD in CBFB-MYH11 AML in terms of relapse rate (Table 
2), no effect was noted on overall survival in multivariate analysis, probably due to the 
relatively high response rates of inv(16) AML to salvage treatment.
71
, and thereby no 
recommendation is made for a change in therapy (for more details, see Suppl. text).  
MRD monitoring after two cycles of chemotherapy and after end of therapy should be 
performed as described in the molecular paragraph (see also Suppl. Text). It should be 
noted that low, stable levels of transcripts may be detectable by PCR for years after 
initial diagnosis without evidence of disease relapse.
72
 
 
RUNX1-RUNX1T1 (t(8;21)) 
As with CBFB-MYH11 positive AML, MRD assessment during the treatment phase of 
patients with RUNX1-RUNX1T1 positive AML is valuable for establishment of baseline 
transcript levels, but, with the controversies in prognostic impact of achieving MRD 
negativity either in PB or in BM (Table 2)
73,74
 (details in Suppl. Text), there is no time 
point or MRD threshold during the active treatment phase that should trigger a 
recommendation to change therapy in patients with RUNX1-RUNX1T1 positive AML. 
MRD negativity at earlier time points was not prognostically-relevant in patients with 
RUNX1-RUNX1T1 fusion.
73,74
 A >3 log reduction in BM between diagnosis and the end of 
induction 1
64
 or consolidation
74
 was associated with significantly different relapse rates 
and a trend for longer OS in multivariate analysis. Patients who do not achieve > 3 log 
reduction in transcripts have poor outcomes but it is unclear whether this can be 
improved with allogeneic stem cell transplantation. 
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AML with NPM1 Mutation, with or without other, concomitant mutations 
MRD for NPM1 can be assessed by quantitative RT-PCR. The presence of measurable 
NPM1 transcripts in PB after at least 2 cycles of cytotoxic chemotherapy is associated 
with a high risk of relapse (>80%, Table 2).
61
 We recommend monitoring of NPM1 
transcripts in BM and PB, if possible.
61
  If NPM1 MRD remains negative in PB but positive 
in BM after the end of treatment, transcripts should be closely monitored in PB and BM 
every 4 weeks for at least 3 months.
61
 If an upward trajectory of MRD, as defined by a 
log increase in either BM or PB, is detected, consideration should be given to salvage 
treatment.
16,55,75
 If a rising MRD titer is not confirmed or MRD becomes undetectable 
then retesting may be performed at 3 month intervals for at least the first 2 years after 
the end of treatment.
54,55,61
  
 
AML with BCR-ABL1 
BCR-ABL positive AML was included as a provisional entity in the 2016 WHO 
classification.
76
 Nearly half of the patients present with the p190 transcript, which is 
rarely found in CML patients.
76
 The prognostic value of BCR-ABL MRD in AML is largely 
unknown and therefore no specific recommendations on clinical cutoffs and their 
prognostic impact in AML patients can be given.  
 
Other molecular MRD markers 
MRD thresholds and time points for other molecular MRD markers have not been 
defined sufficiently to provide recommendations.
16
 Based on current experience with 
fusion genes, we recommend to report the results of future MRD studies for 
achievement of MRD negativity in PB and BM for the time points after 2 cycles of 
chemotherapy and after the end of treatment.  
 
AML subgroups NOT including APL, CBF AML, and AML with NPM1 mutation  
MRD for patients not included in the molecularly defined subgroups APL, CBF AML, AML 
with NPM1 mutation and AML with BCR-ABL1, should be measured using MFC. Having 
undetectable levels of MRD using MFC is associated with significantly better outcomes 
than having measurable disease
4,52,60
, even in the setting of allogeneic stem cell 
transplantation.
28,30  
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Pre-transplant MRD 
Evidence is accumulating that the presence of MRD assessed by MFC immediately prior 
to alloHSCT is a strong, independent predictor of post-transplant outcomes in AML.
77
 In 
a recent update, Walter et al showed that MRD status had strong predictive value both in 
the ablative and non-myeloablative transplant setting with MRD defined depth of 
response prior to transplant being the most important predictor of transplant outcome. 
3,78
 Unfortunately, conversion from MRD positivity pre-transplant to MRD negativity 
after myeloablative conditioning does not substantially improve relapse rate or OS.
79  
On the other hand, in NPM1 mutated patients, MRD had prognostic impact
80
, while only 
in patients who achieved suboptimal reduction (<4 log
10
) of NPM1 levels after 
chemotherapy, alloHSCT resulted in improved overall survival. However, no prospective 
studies using MRD to guide post-remission therapy are available at the time of this 
publication. 
 
Recommendations for MRD monitoring in clinical trials 
CR
MRDPOS
  patients have inferior outcomes even in the setting of alloHSCT representing 
an unmet medical need, and should be considered for enrollment in controlled clinical 
trials. In order to assess whether eradication or reduction of MRD using either existing 
or experimental therapies can a) be accomplished or b) result in improved outcomes, 
should be a goal of clinical trials. 
All clinical trials should require molecular and/or MFC MRD at all times of evaluation of 
response, using the technical guidelines in this manuscript.
4,29,33
  
 
Use of MRD as a surrogate endpoint for survival to accelerate drug approval 
Clearly MRD is used  in clinical practice to guide the care of individual patients, but more 
data are required to establish the use of MRD as a surrogate end-point for clinical trials 
in AML.
4
 If MRD negativity is established as a surrogate endpoint for survival, it is likely 
to be helpful for the evaluation of new drugs, possibly accelerating drug approval or, 
stopping development of suboptimal drugs or treatment strategies.  Currently, two 
studies strongly suggest that MRD can be used as a surrogate for overall survival 
endpoints. In CBF-AML, better clinical outcomes with higher dosage of daunorubicin, 
was found to be associated with MRD level
81
, while in another study, improved overall 
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survival with the addition of gemtuzumab ozogamicin to standard induction therapy,  
correlated with MRD status.
82
 
 
Concluding remark 
 
Recommendations for the MFC, molecular and clinical aspects are summarized in Table 
3. 
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Table 1 . Key studies on the prognostic value of MRD by Multi Parameter Flow Cytometry* 
Publication Multi Center 
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% LAIP Number of 
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MRD 
measurement 
following 
Cut-off MRD level 
 
I                              C                    postTx 
Univariate 
analysis 
significant for 
Multivariate 
analysis 
significant for 
Study details 
San Miguel et al
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 N A 46% 53 I, C <0.05%              0.2% RFS, OS RFS 
 
Venditti et al 
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  Y A 70% 56 I, C 0.045%            0.035% I;- 
C:RFS, OS 
I:- 
C:RFS, OS 
 
San Miguel et al 
85
  A 75% 126 I <0.01%,                - 
0.01-0.1%            - 
0.1-1%                  - 
>1%                       -  
 
RFS,OS RFS MRD>1%:   3 yr RR:    85% 
MRD 0.1-1.0%:  3 yr RR:45% 
MRD 0.01-0.1%: 3yr RR 14% 
MRD <0.01%: 3yr RR: 0% 
Sievers et al
86
 Y C ? 252 I
1
 0.5% RFS,OS RFS,OS 3 yr OS 69% (MRD neg) vs  
41%(MRD pos) 
Kern et al 
87
 Y A 100% 106 Day 16 Log difference 
2.11 
CR, EFS, RFS, OS EFS, RFS  
Kern et al 
88
 N A 100% 62 I,C Log difference      Log difference          
2.11                          2.53 
 
I:RFS 
C:RFS,OS 
I: RFS 
C:RFS 
 
Feller et al 
34
 N A 100% 72 I
1
, I
2
, C, PBSCT I
1
:1%                     0.11%          0.13%      
I
2
:0.14% 
I
1
, I
2
, C, 
PBSCT;RFS,OS 
I
1
, I
2
, C, 
PBSCT;RFS,OS 
 
Buccisano et al 
89
 A A 89% 100 I,C 0.035%                 0.035%  I andC: 
RR,RFS,OS 
I:- 
C: RR,RFS,OS 
5 yr RFS  72% (MRD neg) vs  
11%(MRD pos) 
Langebrake et al
90
  Y A, C ? 150 Day 15, I, I
2
, C 0.1-2%               0.1-1.3% Day 15, I;RFS - MRD similar EFS as traditional 
Risk factors 
Maurillo et al
91
 
 
Y A ? 142 I, C 0.035%                 0.035% I and C; RFS, OS I and C; RFS, OS 5 yrs RR 60%(MRD pos)vs 16% 
9MRD neg) 
Al Mawali et al
92
 N A 94% 54 I, C 0.15%                    0.15% I: RFS,OS 
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I: RFS,OS 
C:- 
 
Van der Velden et al 
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, C, end of 
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: RFS, OS I
1
:RFS, OS 3yr RFS 64%(MRD pos) vs 14% 
(MRD neg ) 
Loken et al
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I
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I
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Inaba et al
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1
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2
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Cut off points between 0.05-0.8 
are all significant 
Freeman et al 
30
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, I
2
,  <0.1%                    <0.1%  I
1
:RFS, OS 
I
2
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Walter et al 
32
 N A, C 100% 253 Pre Tx <0.1% DFS 
OS 
 MRD predictive in CR1 andCR2 
 *Adapted from Ossenkoppele, G., & Schuurhuis, G. J. 
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?, not known; A, adult; C, consolidation; Ch, children; CIR, cumulative incidence of relapse;DFS, disease-free survival; diff., difference; I, 
induction treatment; I
1
, induction cycle 1; I
2
, induction cycle 2C; N, no;LAIP, Leukemia associated phenotype; MA,myeloablative; NMA, non 
myelo-ablative,PBSCT, peripheral blood stem cell transplantation; Pop., population; pts, patients; OS, overall survival, Ref., reference; RR, 
relapse risk; Tx, transplantation; Y, yes. 
  
Buccisano et al
94
 Y A ? 210 I,C 0.035%                 0.035% I,C:DFS, OS I,C: DFD, OS MRD negativity gives 5yr DFS : 
57vs13% in elderly AML 
Araki et al
78
 N A 100% 359 Pre Tx 0.1%  OS,PFS,RFS 3yr RR 67% (MRD pos) vs 
22%(MRD neg) 
Vidriales et al
95
 Y A 100% 306 At the time of 
morphological 
CR 
<0.01%,                
0.01-0.1%             
>0.1%                   
 
RFS RFS Multivariate analysis revealed 
MRD, age and cytogenetics as 
independent variables. 
Cytogenetics and MRD are 
complementary in a scoring 
system 
Tierens et al
96
 Y C 78% 101 Day 15, pre C 0.1%                         0.1% Day 15:EFS,OS 
Pre C: EFS,OS 
Day 15:EFS,OS 
Pre C:EFS,OS 
EFS at 5 yrs 65%( MRD neg) vs 
22%i(MRD pos) 
Rubnitz et al
97
 Y C (1-21yrs) ? 216 I
1
, I
2 
<0.1%,                - 
0.1-1%            - 
>1%                   
EFS 
OS 
I
1 , 
I
2
 :EFS 
I
1
, I
2 :
OS 
I
1
:CIR at 3yrs 38.6 %for MRD pos 
and 16.9% for MTD neg 
I
2
:56.3% vs 16.7% 
Walter et al
98
 
N A 100% 241 Pre TX 0.1% DFS, OS, relapse DFS,OS,relapse Negative impact of MRD on post 
transplant MRD is similar after 
NMA and MA conditioning  
Table 2. Prognostic thresholds for molecular MRD markers in AML patients who are in complete morphologic remission 
 
Gene Number of 
patients 
Time point PB vs. BM cDNA 
vs. 
DNA 
Favorable 
prognostic 
cutoff 
(proportion 
of patients) 
Associated risk Sensitivity of 
the assay 
Reference  
NPM1 194 After 2 cycles of 
chemotherapy 
PB cDNA Negative 
(84.5%) 
 
3-year CIR 30% (vs 
82% if positive), 3-
year OS 75% (vs 24% 
if positive) 
10
−5 
(range, 10
−3.7
 to 
10
−7.1
) 
Ivey et al.
61
  
NPM1 137 After 2 cycles of 
chemotherapy 
BM cDNA Negative 
(19%) 
 
4-year CIR 6.4% (vs 
53% if positive), 4-
year OS 90% (vs. 56% 
if positive) 
10
-5 
to 10
-6
 
 
Krönke et al.
99
  
NPM1 82 After 2 cycles of 
chemotherapy 
BM cDNA Negative  
(26%) 
3-year OS 84% (vs 
76% if NPM1/ABL 
≤1% vs 47% if 
NPM1/ABL >1%) 
 
Shayegi et al.
75
  
NPM1 194 At end of 
treatment 
PB cDNA Negative 
(92%) 
 
3-year OS 80% (vs 
not estimable if 
positive) 
10
−5 
(range, 10
−3.7
 
to 10
−7.1
) 
Ivey et al.
61
 
NPM1 131 (for PB) After 1 or 2 
induction cycles 
PB cDNA ≥4log10 
reduction 
(55%) 
3-year CIR 20.5% (vs 
65.8% if <4log10 
reduction); 3-year OS 
91-93% (vs 40.8% if 
<4log10 reduction) 
0.01% Balsat et al.
80
  
NPM1 129 At end of 
treatment 
BM cDNA Negative 
(48%) 
 
4-year CIR 15.7% (vs 
66.5% if positive), 4-
year OS 80% (vs. 44% 
if positive) 
10
-5 
to 10
-6
 
 
Krönke et al.
99
 
NPM1 80 At end of 
treatment 
BM cDNA Negative 
(49%) 
1-year CIR 37% 
(vs 63% if NPM1/ABL 
≤1% vs 85% if 
NPM1/ABL >1%); 2-
year OS 82% (vs 61% 
if NPM1/ABL ≤1% vs 
45% if NPM1/ABL 
>1%) 
10
-5
 
Shayegi et al.
75
  
NPM1 136 In follow-up BM cDNA < 200 copies 
(68% of 
patients 
completing 
chemothera
py) 
No relapses occurred  
10
-5 
to 10
-6
 
 
Krönke et al.
99
  
RUNX1-
RUNX1T1 
94 At end of 
treatment 
PB cDNA Negative 
(70%) 
 
4-year CIR 23.6% (vs 
50.9% if positive), 4-
year OS 96% (vs 
63.6% if positive) 
10
-5
 
Willekens et al.
74
  
RUNX1-
RUNX1T1 
120 
 
 
 
 
94 
At end of 
treatment 
 
 
 
At end of 
treatment 
BM 
 
 
 
 
BM 
cDNA 
 
 
 
 
cDNA 
Negative 
(49%) 
 
 
 
Negative 
(30%) 
4-year EFS 81% (vs 
61% if positive), 4-
year OS 93% (vs 67% 
if positive) 
 
4-year CIR 28.2% (vs 
33.8% if positive), 4-
year OS 86.4% (vs 
87.7% if positive, 
n.s.) 
10
-6
 
 
 
 
 
 
10
-5
 
Agrawal et al.
73
  
 
 
Willekens et al
74
  
RUNX1-
RUNX1T1 
163 In follow-up PB cDNA <100 
copies/10
5
 
ABL copies 
(85%) 
5-year CIR 7% (vs 
100% if ≥100), 5-year 
OS 95% (vs 59% if 
≥100) 
10
-5
 
Yin et al.
71
  
RUNX1- 163 In follow-up BM cDNA <500 5-year CIR 7% (vs 
10
-5
 
Yin et al. 
71
 
RUNX1T1 copies/10
5
 
ABL copies 
(83.5%) 
100% if ≥500), 5-year 
OS 94% (vs 57% if 
≥500) 
CBFB-
MYH11 
115 At end of 
treatment 
PB cDNA <10 
copies/10
5
 
ABL copies 
(80%) 
5-year CIR 36% (vs 
78% if ≥10) 
10
-5
 
Yin et al. 
71
 
CBFB-
MYH11 
115 In follow up PB cDNA <10 
copies/10
5
 
ABL copies 
(69%) 
5-year CIR 7% (vs 
97% if ≥10), 5-year 
OS 91% (vs 57% if 
≥10) 
10
-5
 
Yin et al. 
71
 
CBFB-
MYH11 
115 In follow up BM cDNA <50 
copies/10
5
 
ABL copies 
(73%) 
5-year CIR 10% (vs 
100% if ≥50), 5-year 
OS 100% (vs 25% if 
≥50) 
10
-5
 
Yin et al. 
71
 
PML-
RARA 
301 At end of 
treatment 
(ATRA+anthracy
cline based) 
BM cDNA Negative 
(95%) 
3-year CIR 11% (vs 
34% if positive) 
At least 10
-3
 
Grimwade et al.
67
  
PML-
RARA 
115 At end of 
treatment 
(ATO+ATRA, low 
and interm. risk 
APL) 
BM cDNA Negative 
(100%) 
4.2-year CIR 1.9% n.d. Platzbecker et al.
68
  
WT1 129  After induction PB or BM cDNA ≥ 2 log 
reduction in 
the same 
tissue (PB or 
BM) 
(62%) 
5-year CIR 40% (vs 
75% if <2 log) 
10
-4
 
Cilloni et al.
45
  
WT1 584 At end of 
treatment 
BM cDNA <10 copies 
(32%) 
3-year CIR 25% (vs 
45% if 10-100 copies 
vs 72 of >100 
10
-4
 Nomdedeu et al.
46
  
copies), 3-year OS 
72% (vs 59% if 10-
100 copies vs 30% if 
>100 copies) 
 
Abbreviations: PB, peripheral blood; BM, bone marrow; CIR, cumulative incidence of relapse; OS, overall survival; 
n.s., not significant, ATO, arsenic trioxide; ATRA, all-trans retinoic acid. 
 
 Table 3. ELN recommendations for MRD assessment 
Flow 
cytometry 
Recommendations 
1. Use the following markers in a MRD panel:  
CD7, CD11b, CD13, CD15, CD19, CD33, CD34, CD45, CD56, CD117, 
HLA-DR (backbone: CD45,CD34,CD117, CD13,CD33,FSC/SSC) 
If necessary, add a “monocytic tube” containing: 
CD64/CD11b/CD14/CD4/CD34/HLA-DR/CD33/CD45. 
2.  Integrate the classic LAIP approach with the different-from-normal 
(DfN) approach. To trace all aberrancies (at and beyond diagnosis, 
including newly formed post-diagnosis aberrancies) apply a full panel 
both at diagnosis and at follow up. 
3. Aspirate 5 - 10 mL BM and use the first pull for MRD assessment. At 
present PB, with its lower MRD content, should not be used for MRD 
assessment. 
Pull as low as desirable BM volume since contamination with PB 
increases with BM volume 
4. Estimate the contamination with PB, especially when a first pool of 
BM was impossible. 
5. Use 500,000 to one million white blood cells, use the best aberrancy 
available and relate it to CD45+ white blood cells. 
6. To define “MRD-negative” and “MRD-positive” patient group, a cut-
off of 0.1% is recommended. 
7. If true MRD <0.1% is found, report this as “MRD-positive <0.1%, may 
be consistent with residual leukemia”. If applicable the comment “this 
level has not been clinically validated” should be added. 
8. In a multicenter setting transport and storage of full BM at room 
temperature for a period of 3 days is acceptable. 
9. Single center studies with no extensive experience on MFC MRD are 
strongly discouraged 
  
 
Molecular 
Biology 
Recommendations 
1. Molecular MRD analysis is indifferent to the anticoagulant used during 
cell sampling and thus both heparin or EDTA can be used as 
anticoagulant. 
2. Aspirate 5 - 10 mL BM and use the first pull for molecular MRD 
assessment. 
3. WT1 expression should not be used as MRD marker, unless no other 
MRD marker is available in the patient. 
4. Do not use of mutations in FLT3-ITD, FLT3-TKD, NRAS, KRAS, DNMT3A, 
ASXL1, IDH1, IDH2, MLL-PTD and expression levels of EVI1 as single 
MRD markers. However, these markers may be useful when used in 
combination with a second MRD marker. 
5. We define molecular progression in patients with molecular 
persistence as an increase of MRD copy numbers ≥ 1 log
10
 between 
any two positive samples. Absolute copy numbers should be reported 
in addition to the fold increase to enable the clinician to make his/her 
own judgments. 
6. 
 
We define molecular relapse as an increase of the MRD level of ≥ 1 
log
10
 between two positive samples in a patient who was previously 
tested negative.  
The conversion of negative to positive MRD in PB or BM should be 
confirmed 4 weeks after the initial sample collection in a second 
sample from both BM and PB. If MRD increases in the follow up 
samples ≥ 1 log
10
, molecular relapse should be diagnosed. 
  
 
Clinical Recommendations 
1. Refine morphology-based CR by assessment of  MRD, because CR 
MRD
neg
 is a new response criterium according to the AML ELN 
recommendation 2017. 
Use MRD to refine risk assessment prior to consolidation treatment, 
the post-induction time point closest to consolidation treatment is 
recommended. 
2. MRD monitoring should be considered part of the standard of care for 
AML patients. 
Monitoring beyond 2 years of follow up should be based on the 
relapse risk of the patient and decided individually. 
Patients with mutant NPM1, RUNX1-RUNX1T1, CBFB-MYH11 or PML-
RARA should have molecular assessment of residual disease at 
informative clinical time points. 
3. Not to assess molecular MRD in subtypes other than APL, CBF AML, 
and NPM1-mutated AML 
4. For AML patients NOT included in the molecularly defined subgroups 
above, MRD should be assessed using MFC 
 
During the treatment phase we recommend molecular MRD 
assessment at minimum at diagnosis, after 2 cycles of standard 
induction/consolidation chemotherapy and after the end of treatment 
in PB AND BM. 
During follow up of patients with PML-RARA, RUNX1-RUNX1T1, CBFB-
MYH11, mutated NPM1 and other molecular markers we recommend 
molecular MRD assessment every 3 months for 24 months after the 
end of treatment in BM and in PB. Alternatively, PB may be assessed 
every 4-6 weeks. 
 
5. Failure to achieve an MRD-negative CR, or rising MRD levels during or 
after therapy are associated with disease relapse and inferior 
outcomes and should prompt consideration of changes in therapy 
6. In APL, the most important MRD endpoint is achievement of PCR-
negativity for PML-RARA at the  end of consolidation treatment 
For patients with PML-RARA fusion and low/intermediate risk Sanz 
score who are treated with ATO and ATRA, MRD analysis should be 
continued until the patient is in CR
MRD-
 in BM and then should be 
terminated. 
7. Detectable levels of PML-RARA by PCR during active treatment of APL 
should not change the treatment plan for an individual patient 
8. A change in status of PML-RARa by PCR from undetectable to 
detectable, and confirmed by a repeat sample, should be regarded as 
an imminent disease relapse in APL  
9. Patients with CBF AML should have an initial assessment of MRD after 
two cycles of chemotherapy, followed by serial measurements every 3 
months for at least the first 2 years after the end of treatment 
10. MRD should be assessed pre-transplant. 
11. MRD should be performed post-transplant 
12. All clinical trials should require molecular and/or MFC assessment of 
MRD at all times of evaluation of response 
  
 
   
 
? 
Cell events in LAIP/DfN region but <0.1% 
                  ?background  
                  ?prognostic  
 Needs further evaluation for prognostic significance 
Not in CR by morphology 
No  MRD events detected 
0.05% 
0.1% 
5.0% 
1.0% 
% MRD by LAIP/DfN 
? 
MRD detected 
if <0.1% either clinically  validated  
or ‘may be consistent with residual leukemia’ 
No MRD identified - No LAIP/ DfN events in  good 
MRD negative  -  MRD detected below  the validated 
detection threshold  
? 
MRD  <0.1% or not  detected but suboptimal 
sample  quality or  minor frequency LAIP 
MRD positive 
Figure 1A. MFC MRD scenarios. 
 Sample Quality 
Viability     (sample age)                         Acceptable / Poor           (eg  > 96 hours) 
Total cells acquired 
(for reported LAIP tube) 
 
                        X 
CD45+ cells acquired 
(for reported LAIP tube) 
 
                        X 
Hemodilute                       Yes / no  /  not assessed 
Blast/progenitor %                      X%          Gated by 
                                      (highlight below gate selected for blast %) 
                                   CD34 and/or CD117 
                                   CD45/SSC 
                                   Monocytic markers 
                                   Other  (specify) 
 
 Sample Quality  is  Adequate / Borderline / Inadequate 
 
 
 
MFC MRD 
 
Diagnostic LAIP 
 
 
   Yes   
or No (no LAIP found in diagnostic sample) 
or No adequate diagnostic sample  
LAIP / DfN used 
for MFC MRD 
    Diagnostic      x as % of blasts at diagnosis (coverage) 
or Follow-up  (no diagnostic information)  
or Change (new LAIP  compared to  previous diagnosis  /  
follow-up) 
LAIP / DfN reported   
 
Specificity (detection threshold) 
 
   eg 56+117+34+33+ 
= eg 0.02%  (maximum  % control BM cells in LAIP 
region) 
  
 
 
 
 
 
 
Figure 1B. MFC MRD scenario. 
Example of MFC MRD report template 
 
MFC MRD 
 
   
X%  MFC MRD       X% blasts (or X% myeloblasts) 
 
 
 
CONCLUSION    
 
    MFC MRD not possible  
or MFC MRD positive  
or MFC MRD negative  (can add ‘no MFC MRD identified’ if no MRD 
events) 
or MFC MRD detectable and quantifiable but uncertain 
significance 
    (eg <0.1% or a ?treatment related  or ?pre-leukemic DfN LAIP) 
 
  
 
